| Devatis AG - Ruxolitinib Devatis 5 mg, Tabletten | | 70478 | | 01 | | Ruxolitinib Devatis 5 mg | | Tabletten | | L01EJ01 | | Ruxolitinib | | 24.08.2026 | | |
| | Composition | | ruxolitinibum 5 mg ut ruxolitinibi hemifumaras, lactosum monohydricum 74.8455 mg, hydroxypropylcellulosum, povidonum K 30, carboxymethylamylum natricum A corresp. natrium 0.20 mg, silica colloidalis anhydrica, cellulosum microcristallinum, magnesii stearas, pro compresso. | | Packungsbestandteile | | Comprimés | | | | Principe actif | Concentr. |
|---|
| Ruxolitinibum | 5 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Carboxymethylamylum Natricum A | | | Cellulosum Microcristallinum | | | Hydroxypropylcellulosum | | | Lactose Monohydrate | 74.8455 mg | | Magnesii Stearas | | | Povidonum K | 30 | | Pro Compresso | | | Silica Colloidalis Anhydrica | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 56 | | | A | | Oui |
|
|
